Monitoring the amount of hemolysis is an important quality measure in cell salvage programs, yet traditional methods may fall short in providing reliable, actionable data.
On February 26th, please join us for a deep-dive session with Dr. Tim Maul of Nemours Children’s Health where he will provide a practical look at how transitioning to specific, quantitative markers can enhance the documentation of blood quality and device performance.
Session Highlights:
Clinical significance: Examine the association between plasma-free hemoglobin and clinical risk factors such as mechanical stress and red cell damage.
Evaluating methodology: Compare the technical limitations of indirect hemolysis markers with the clarity of plasma-free hemoglobin measurement.
Simplifying compliance: Explore the operational benefits of FDA-cleared testing and how it simplifies requirements for personnel qualifications and inspections compared to high-complexity laboratory developed tests.
Benchmarking performance: Understand how to use quantitative data to track washout efficiency and plasma clearance rates in cell salvage QC.
Attend our webinar and learn how perfusionists can lead the shift toward more specific, reliable hemolysis assessment to improve overall program oversight.
Speaker: Dr. Timothy Maul, Perfusionist
Date: February 26, 10am PT / 1pm ET
Reserve your spot here
